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This study is concerned with the development of an agent for single photon emission computer to-
mography (SPECT) for imaging inﬂammation and tumor progression. [123I]Iodooctyl fenbufen amide
([123I]IOFA) was prepared from the precursor N-octyl-4-oxo-4-(40-(trimethylstannyl)biphenyl-4-yl)
butanamide with a radiochemical yield of 15%, speciﬁc activity of 37 GBq/mmol, and radiochemical purity
of 95%. Analysis of the binding of [123I]IOFA to COX-1 and COX-2 enzymes by using HPLC and a gel ﬁl-
tration column showed a selectivity ratio of 1:1.3. An assay for the competitive inhibition of substrate
transfer showed that IOFA exhibited a comparable IC50 value compared to fenbufen. In the normal rat
liver, a lower level and homogeneous pattern of [123I]IOFA radioactivity was observed by SPECT. In
contrast, in the rat liver with thioacetamide-induced cholangiocarcinoma, a higher uptake and hetero-
geneous pattern of [123I]IOFA radioactivity was seen as hot spots in tumor lesions by SPECT imaging.
Importantly, elevated COX-1 and COX-2 expressions from immunostaining were found in the bile ducts
of tumor rats but not of normal rats. Therefore, [123I]IOFA was found to exhibit the potential for imaging
tumors that over-express COX.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Non-steroid anti-inﬂammatory drugs (NSAIDs) have been well
recognized for their anti-inﬂammatory efﬁcacy and cancer-
preventing effects. Chronic inﬂammation is associated with an
increased risk of cancer for individuals with inﬂammatory bowel
diseases [1]. Hence, cancer prevention by using NSAIDs is a relevant
concept, and reports on their use for this means can be found in
literature [2,3]. Their inﬂammatorymechanism ismainly associated
with inﬂammatory lipids that are catalyzed by the key enzyme,
cyclooxygenase (COX) [4]. Three types of COX enzymes have been
reported: (1) COX-1, which functions as a house-keeping enzymeal Engineering and Environ-
hu 300, Taiwan.
tudy.
-ND license.and is constitutively expressed in most tissue types; (2) COX-2,
which is a highly inducible enzyme under physiological condi-
tions; and (3) a COX-1 splice variant that is termedCOX-3 [5e7]. COX
mediates the conversion of arachidonic acid (AA) into prostaglan-
dins (PG) via two sequential steps: initial oxidation to PGG2byusing
a cyclooxygenase enzyme and subsequent reduction to an unstable
endoperoxide intermediate PGH2 by peroxidase (POX) [8]. The two
reactions occur in spatially distinct but mechanistically coupled
active sites. The cyclooxygenase active site is located at the end of
a long hydrophobic channel that is broad near the membrane-
binding domain (the lobby) and narrows as it extends toward the
interior of the protein [9,10]. The POX active site is located on the
surface of the protein near the heme cofactor. Prostaglandin endo-
peroxide synthase-1 and -2 (PGHS-1 and -2) are also known as
COX-1 and COX-2, respectively [11]. PGHSs are composed of two
monomers. Each monomer has a physically distinct COX and POX
active site. The two monomers have different conformations, and
they function cooperatively during catalysis in solution. It is clear
H.-L. Huang et al. / Biomaterials 34 (2013) 3355e33653356that the COX reaction is activated through a radical cation inter-
mediate of a hemeemonomer complex that is derived from the
oxidation of the hemeemonomer complex by POX. The key rests in
the fact that the Tyr385 radical should be formed via POX before the
oxidation of AA by COX. COX and POX could maintain their reaction
pathways independently. However, the reaction cycle of COX is
sensitive and could be terminated by various factors, whereas POX
activity is relatively unaffected and can last longer.
The mechanism of inhibition of COXs by traditional NSAIDs is
complicated because AA and the inhibitor interact with COX
reciprocally. In PGHS-1, the conformations of the two AAs in the
AA-COX complexes of the dimer are symmetrical. In contrast, the
two conformations of AAs in PGHS-2 are antisymmetrical [12].
PGHS-2 functions as a conformational heterodimer with an allos-
teric monomer (Eallo) and a catalytic (Ecat) monomer. For example,
some non-substrate fatty acids could bind Eallo to stimulate the rate
of AA oxygenation. Some COX inhibitory NSAIDs and some COX-2
speciﬁc inhibitors function through Eallo, Ecat, or both Eallo and Ecat
[13,14]. In many tumors, high prostaglandin levels are up-regulated
by COX, whereas the degraded enzyme e.g., 15-prostagladin
dehydrogenase (15-PGDH) plays a role in the negative regulation
of prostaglandin levels.
The long-term uptake of NSAIDs and COX-1inhibitors is always
accompanied by adverse side effects such as gastrointestinal tox-
icity [15,16]. Speciﬁc COX-2 inhibitors were developed to overcome
this side effect. However, prolonged use of COX-2 inhibitors results
in other side effects such as cardiovascular events. Furthermore,
very high dosages of COX inhibitors or NSAIDs are frequently
required to exhibit tumor inhibition effects, but only low dosages
are required for inhibiting prostaglandin formation [1,17]. The anti-
tumoral effects are thus probably not only mediated through the
COX pathway but also through an NSAID-activated gene or growth
differentiation factor 15 [1].
Because of the complexity of COX mechanisms such as dual
functionality of the enzyme and close coupling of the two active
sites, agents with unique inhibitory properties are still under
development. Apart from the fact that aspirin irreversibly in-
activates COX-2 by covalently modifying Ecat, other COX inhibitors
have been developed such as (a) time-independent Eallo inhibitors
(ibuprofen with 2-arachidonylglycerol and PGHS-2) or time-
independent Eallo and Ecat inhibitors (ibuprofen with AA and
PGHS-2), and (b) time-dependent Eallo inhibitors (naproxen with
AA and PGHS-2) [11,13,14]. In addition, a number of studies have
focused on developing COX-1 selective inhibitors with very low
gastric ulcerogenic activities [18,19], because inhibiting COX-1
alone is not sufﬁcient to cause gastric damage [20].
Imaging inﬂammation as well as tumor progression has
attracted a great deal of attention recently [21e36]. As a diagnostic
imaging probe for positron emission tomography (PET) or single
photon emission computer tomography (SPECT), cytotoxicity is not
a serious concern because only very low doses (lower than 1/100
the therapeutic dose) are administered to an individual within
a short period [37]. Various PET and SPECT probes based on theHO
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Fig. 1. Enhanced inhibition of cellularstructural characteristics of COX-2 [21e35] and COX-1 [36] speciﬁc
inhibitors have been developed in the past few decades. However,
only rare radiopharmaceuticals have been successfully applied to
imaging inﬂammatory events [36]. The reason for this has been
attributed to the instability of COX-2 enzymes or due to the very
low absolute amount of COX-2 over-expression that is available to
be detected [1].
Because the designs of these radiolabeled COX-2 inhibitors are
mainly based on a triphenyl ring scaffold or biaryl scaffold that
speciﬁcally target the COX-2 enzyme, other types of radiophar-
maceuticals that target the COX-1 enzyme have been re-
investigated [38]. Promising imaging results [39] encouraged us
to prepare octyl fenbufen amide (OFA) [40e42], which are mem-
bers of the NSAID family that do not exhibit COX selectivity (Fig. 1).
Speciﬁcally, OFA was discovered through parallel solution phase
synthesis. Moreover, the octyl group can be used to modify its anti-
tumoral cytotoxicity (EC50 ¼ 20 mM) in comparison with its parent
fenbufen [42]. Arachidonyl ethanolamide (AEA) was reported to be
poly-unsaturated fatty acyl amide that exerts immunomodulatory
activity through unspeciﬁed anchoring to the active site of COX-2
(as well as COX-1) [43,44]. Because both AEA and OFA share
a similar structural feature in terms of their eight-carbon chain
length, the inhibition of cellular growth by OFA was postulated to
be mediated through such an interaction. Hence, OFA might be
a tracer suitable for imaging COX function. Taken together, OFAwas
chosen for radiolabeling and for imaging of COXs in vivo. Speciﬁ-
cally, OFAwas labeled with radioiodine 123I for non-invasive in vivo
imaging using SPECT.
2. Materials and methods
2.1. General
All of the reagents and solvents that we used were purchased from Sigmae
Aldrich, Malingkrodt, Acros, Alfa, Tedia, or Fluka. CH2Cl2 and toluene were dried
over CaH2, and MeOH was dried over Mg and distilled prior to use. DMF and 1,4-
dioxane were distilled under reduced pressure. The reagents and solvents were
reagent grade. Preparation of organostannyl compound 3 was carried out in dried
glassware under nitrogen at positive pressure. The eluents that were used for ﬂash
chromatography such as EtOAc, acetone, and n-hexane were of industrial grade and
distilled prior to use; MeOH and CHCl3 were reagent grade and used without further
puriﬁcation. Thin layer chromatography (TLC) was performed withMERCK TLC silica
gel 60 F254 precoated plates. The starting materials and products were visualized
with UV light (254 nm). Further conﬁrmation was carried out by staining with 5%
p-anisaldehyde, ninhydrin, or ceric ammonium molybdate under heating. Flash
chromatography was performed using Geduran Si 60 silica gel (230e400 mesh).
Melting points were measured with MEL-TEMP and were uncorrected. NMR spec-
troscopy, including 1H NMR (500 MHz) and 13C NMR (125 MHz, DEPT-135), was
performed on a Varian Unity Inova 500 MHz. D-solvents that were employed for
NMR, including CD3OD, CDCl3, and C6D6, were purchased from Cambridge Isotope
Laboratories, Inc. Low-Resolution Mass Spectrometry (LRMS) was performed on an
ESI-MS spectrometer by employing a VARIAN 901-MS Liquid Chromatography
TandemMass Q-Tof Spectrometer at the Department of Chemistry of National Tsing-
Hua University (NTHU). High Resolution Mass Spectrometry (HRMS) was performed
using a varian HPLC (prostar series ESI/APCI) coupled mass detector from a Varian
901-MS (FT-ICR Mass) and a triple quadrapole.
A commercial colorimetric COX (ovine) inhibitor screening assay kit was pur-
chased from Cayman Chemical Ltd (760111). The assay kit contained both COX-1 andN
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H.-L. Huang et al. / Biomaterials 34 (2013) 3355e3365 3357COX-2 assay reagents. The speciﬁc activities of both the two enzymes were equiv-
alent according to the suppliers. A commercial PTFE ﬁlter (0.45 mm) was purchased
fromMillipore. An Elisa reader of 96 well (Biochrom, Anthos Zenyth 3100) was set at
lmax ¼ 595 nm according to the kit supplier. The IC50 calculation was made by using
commercial software of Graph Pads.
[123I]NaI was produced on an EBCO TR30 cyclotron (30 MeV) via the
124Xe(p,2n)123Cs/ 123Xe/ 123I at Nuclear Energy Research Institute, Taiwan. All
irradiations were carried out at a beam current of 120 mA, which gave an average
integrated current at the target of 300 mA h. After end of bombardment (EOB), the
target was cooled for 6e8 h for the 123Cs to decay to 123Xe and transform further into
123I. The target was washed with dilute NH4OH (0.0016 N, 500 mL) and eluted with
NH4OH (0.16 N, 4 mL). The eluents were immediately loaded onto an alumina-B
cartridge that had been pretreated with acetic acid (5.8 N, 10 mL). Followed by
loading onto a second column of resin (AG50W-X8) that was pretreated with NaOH
(1 N, 4 mL), the eluents were combined (2e3mL) and a volume that ranged from 0.3
to 0.6 mL was used throughout the subsequent radiolabeling experiment. Radio-
labeling was performed in a hoodwith sufﬁcient ventilation and that had been ﬁtted
with a hepaﬁlter for operation with 123I. [123I]IOFA 2was puriﬁed by HPLC for which
the components consisted of a Waters 510 pump, a linear UVIS detector (254 nm)
that was placed in series with a Berthhold g-ﬂow detector on a ZORBAX SILcolumn
(250mm 9.4 mm, 5 mm). The HPLC was run at 3 mL/minwith MeOH/CHCl3 1:99 as
the mobile phase. Quality analysis of [123I]IOFA 2 was performed on the same HPLC
setup. The settings for the radioactive ligand binding assay included a gel ﬁltration
column that consisted of TSKgel G3000PWxl 7.5  300 (mm) with a particle size of
10 mm, which was purchased from Tosoh Bioscience LLC. The corresponding eluting
conditions including PBS buffer and ﬂow rate of 1 mL/min were employed
throughout the experiment. The identity of [123I]IOFA 2 was conﬁrmed using an
authentic sample 2 on the HPLC chromatogram after coinjection. The peak area of
the UV absorbance at 254 nm that should have corresponded to authentic sample 2
was calculated by interpolating a standard curve that relatedmass to UV absorbance.
Only a speciﬁc activity of below 36 GBq/mmol could be measured accurately. Radi-
oactive measurements were performed using a Capintec R15C dose calibrator.
All the in vivo experiments were performed in compliance with the NHMRC
Taiwan Code of Practice for the care and use of animals for scientiﬁc purposes. Male
SpragueeDawley (SD) rats that were 49 weeks old were obtained from the Animal
Research Center (Chang-Gung Memorial Hospital, Taiwan). The rats were housed
under constant environmental conditions and were allowed free access to food and
water throughout the experimental period. In vivo studies were performed in
a thioacetamide-induced cholangiocarcinoma rat (37th week post administration)
along with a normal rat as a control.
The rats were anaesthetized via inhalant isoﬂurane (Forthane, Abbott) in
200 mL/min oxygen during the imaging study. SPECT system (X-SPECT/CT, Gamma
Media, Northridge, CA, USA) was used for small animal imaging experiments.
2.2. Chemical preparation
2.2.1. 4-(40-iodobiphenyl-4-yl)-4-oxobutanoic acid 1
A mixture of succinic anhydride (893 mg, 9.0 mmol) and AlCl3 (2.52 g,
18.8 mmol, 2.1 eq) in CH2Cl2 (45 mL) was stirred at room temperature for 20 min
while the mixture became a milky paste. The viscous mixture was moved to an
ice bath and stirred in the dark for 2 min. Upon the addition of commercial
4-iodobiphenyl (2.5 g, 9.0 mmol), the mixture turned dark green. Stirring was then
continued for 1 h. TLC (acetone:n-hexane ¼ 3:7) was used to observe the con-
sumption of iodobiphenyl (Rf¼ 0.87) and the formation of product 1 (Rf¼ 0.21). The
mixture was poured into a mixture of HCl (12 N, 250 mL) in ice (500 g), and stirring
was carried out until the dark green color disappeared, and yellow suspended solids
were formed. After ﬁltering the mixtures using a Büchner funnel, the residual solid
was collected. Themixturewas dissolved in aqueous NaOH (1 N, 250mL). EtOAcwas
then added to partition the undesired organic impurities, whichwere then removed.
The aqueous layer was collected and HCl (12 N) was added to acidify the solution
until the solids precipitated. The mixture was transferred to a Büchner funnel where
it was washed with distilled water to remove the rest of the acid. The residue was
dried under reduced pressure, and a fruity yellow solid was obtained at a crude yield
of 89% (3.0 g). Although additional puriﬁcation using HPLC with various eluents was
performed, identiﬁcation of desired product 1 and the deiodinated byproduct was
difﬁcult. The ratio of iodo and deiodinated byproducts was determined through
structural modiﬁcation as described in the subsequent preparation. Calcd. C16H13IO3
[M]þ ¼ 379.99, ESI þ Q-TOF MS, M ¼ 380.0 (m/z), [MþNa]þ ¼ 403.0, and
[2MþNa]þ ¼ 782.9; 1H NMR (500 MHz, CD3OD): d 2.89 (t, J ¼ 6.5 Hz, 2H, aliphatic),
3.50e3.53 (m, 2H, aliphatic), 7.62e7.65 (m, 2H, Ar), 7.83e7.85 (m, 1H, Ar), 7.91e7.93
(m, 2H, Ar), 7.99 (d, J ¼ 7.5 Hz, 1H, Ar), and 8.24 (d, J ¼ 8.0 Hz, 2H, Ar).
2.2.2. 4-(40-iodobiphenyl-4-yl)-N-octyl-4-oxobutanamide (IOFA) 2
To a two-necked round-bottomed ﬂask that contained a mixture of 1 in DMF
(15 mL) was added HBTU (O-benzotriazol-1-yl-N,N,N0 ,N0 ,-tetramethyluronium hex-
aﬂuorophosphate; 998 mg, 2.6 mmol) and diisopropyl ethylamine (680 mg, 0.9 mL,
5.2 mmol, 2 eq) in sequence. Stirring was then carried out for 30 min after which
commercial octan-1-amine (510 mg, 3.9 mmol, 1.5 eq) was added. Stirring was then
carried out for another 15min. TLC (acetone/n-hexane¼ 3:7)was used to observe theconsumption of the startingmaterial 1 (Rf¼ 0.21) and the formation of the product 2
(Rf ¼ 0.56). The mixture was concentrated under high vacuum at 60 C. The residue
was partitioned between aqueous HCl (1 N, 30 mL  2) and CHCl3 (50 mL). The
organic layers were combined and then concentrated under reduced pressure. The
residue thatwas obtainedwas puriﬁed by usingﬂash chromatographywith an eluent
of acetone/CHCl3¼1:29 to provide pale yellow solid 2with a plastic-like smell at 73%
yield (938mg). An analytic samplewas fractionated byHPLCwith an eluent ofMeOH/
CHCl3 ¼ 1:99, tR ¼ 17.3 min white solid, mp: 181e182oC; Calcd. C24H30INO2
[M]þ¼491.1, ESIþQ-TOFMS,M¼491.1(m/z), [MþH]þ¼492.1, and [MþNa]þ¼514.1;
HRMS-ESI, Calcd. [MþH]þ ¼ 492.13995 and [MþNa]þ ¼ 514.12189; found:
[MþH]þ ¼ 492.13955 and [MþNa]þ ¼ 514.12173; 1H NMR (500 MHz, CDCl3): d 0.87
(t, J¼ 7.0Hz, 3H, octyl, CH3),1.26e1.32 (m,10H, octyl, CH2),1.50 (t, J¼ 7.0Hz, 2H, Octyl,
CH2), 2.62 (t, J ¼ 6.5 Hz, 2H, aliphatic, CH2), 3.24 (q, J ¼ 7.0 Hz, 2H, octyl, CH2), 3.39
(t, J¼7.0Hz, 2H, aliphatic, CH2), 5.77 (bs,1H, amide), 7.35 (d, J¼8.5Hz, 2H, Ar), 7.63 (d,
J¼ 8.0 Hz, 2H, Ar), 7.79 (d, J¼ 8.5 Hz, 2H, Ar), and 8.05 (d, J¼ 8.5 Hz, 2H, Ar); 13C NMR
(125 MHz, CDCl3): d 14.07 (Octyl-CH3), 22.62 (Octyl, CH2), 26.88 (Octyl, CH2), 29.18
(Octyl, CH2), 29.23 (Octyl, CH2), 29.59 (Octyl, CH2), 30.37 (Octyl, CH2), 31.76 (NHeCOe
CH2), 34.21 (AreCOeCH2), 39.68 (COeNHeCH2), 94.28 (Ar, CeI), 127.00 (Ar, CH),
128.78 (Ar, CH), 129.00 (Ar, CH),135.61 (Ar, CeCO),138.06 (Ar, CH),139.32 (Ar, CeAr),
144.69 (CeAr), 171.88 (NHeCO), and 198.64 (AreCO).
2.2.3. N-octyl-4-oxo-4-(40-(trimethylstannyl)biphenyl-4-yl)butanamide 3
To a ﬂask (10 mL) containing IOFA 2 (100 mg, 0.2 mmol) in 1,4-dioxane (1 mL)
bis(triphenylphosphine)palladium dichloride (5 mg, 0.007 mmol, 0.03 eq) and
hexamethylditin (237 mg, 0.15 mL, 0.72 mmol, 3.6 eq) were added sequentially.
The mixture was warmed to 85 C, and stirring was carried out for 15 min. TLC
(acetone/CHCl3 ¼ 1:19) was used to follow the consumption of the starting material
2 (Rf¼ 0.50) and the formation of the product 3 (Rf¼ 0.55). The mixture was ﬁltered
through a celite pad, and the ﬁltrates were concentrated under reduced pressure.
The residue that was obtained was puriﬁed using ﬂash chromatography with the
eluent EtOAc/n-hexane ¼ 2:8 to provide a white paste 3 at 56% yield (61 mg). An
analytic sample was obtained through fractionation with HPLC using an eluent of
EtOAc/n-hexane ¼ 1:1, tR ¼ 11.0 min. The product smelled like the combination of
plastic and acid. Calcd. C27H39NO2Sn [M]þ ¼ 525.20 (41.5%), 527.20 (75.4%), 528.20
(44.8%), 529.20 (100.0%), ESI þ Q-TOF MS, [MþH]þ ¼ 526.0 (29%), 528.1 (71%), 529.0
(43%), and 530.1 (100%); HRMS-ESI, Calcd. [MþH]þ ¼ 530.20810 and
[MþNa]þ ¼ 552.19005; found: [MþH]þ ¼ 530.20767 and [MþNa]þ ¼ 552.19021; 1H
NMR (500 MHz, C6D6): d 0.25 (t, J ¼ 27.5 Hz, 9H, SneCH3), 0.89 (t, J ¼ 7.5 Hz, 3H,
aliphatic), 1.14e1.20 (m, 8H, aliphatic), 1.25e1.30 (m, 4H, aliphatic), 2.39 (t, J¼ 6.5 Hz,
2H, aliphatic), 3.12e3.17 (m, 4H, aliphatic), 5.11 (bs,1H, amide), 7.15e7.50 (m, 6H, Ar),
and 7.95 (d, J ¼ 8.5 Hz, 2H, Ar); 13C NMR (125 MHz, CDCl3): d 9.55 (SneCH3), 14.06
(Octyl-CH3), 22.61 (Octyl, CH2), 26.88 (Octyl, CH2), 29.17 (Octyl, CH2), 29.23 (Octyl,
CH2), 29.57 (Octyl, CH2), 30.41 (Octyl, CH2), 31.75 (NHCOeCH2), 34.22 (NHCOeCH2),
39.66 (CONHeCH2), 126.70 (Ar, CH), 127.17 (Ar, CH), 128.66 (Ar, CH), 135.23 (Ar, Ce
CO), 136.40 (Ar, CH), 139.62 (Ar, CeSn), 142.69 (Ar, CeAr), 145.95 (Ar, CeAr), 171.97
(COeNH), 198.70 (AreCO).
2.3. Preradiolabeling of organostannyl compound 3 with non-radioactive NaI
A sample vial (50 mL) that contained NaI (7.8 mg, 0.052 mmol, 7.5 eq) and
doubly distilled water (0.5 mL) was sonicated for 2 min. A solution of glacial AcOH
and 30% H2O2 (1:1.5 v/v) was added, and sonication was carried out for a further
1 min. After adding the solution of organostannyl compound 3 (4 mg, 0.007 mmol,
1 eq) in CH2Cl2 (2 mL) the mixture was sonicated for 20 min. The quenching reagent
Na2S2O3 (0.1 M, 10 mL) was then added. Next, the mixture was partitioned by using
H2O (5 mL) and CH2Cl2 (10 mL). The organic layer was collected for subsequent
loading onto a neutral alumina cartridge followed by washing with a solution of
CH2Cl2 and MeOH (2:1, v/v, 10 mL). After being concentrated under reduced pres-
sure, the residue was puriﬁed with HPLC (Si-100) using the eluent
CH2Cl2:MeOH ¼ 99:1 to provide the desired fractionations: tR ¼ 17.2 min for com-
pound 2 and tR ¼ 18.2 min for the destannylated byproduct OFA (see also the
radiochemical labeling section). After being concentrated under reduced pressure,
the desired compound 2 was obtained at 50% yield (2 mg).
2.4. Radiochemical labeling of 4-(40-[123I]iodobiphenyl-4-yl)-N-octyl-4-
oxobutanamide [123I]IOFA 2
To a round-bottomed ﬂask (25 mL) that was charged with a mixture of aqueous
[123I]NaI (75 mCi) in H2O (less than 0.6 mL), glacial AcOH (3.5 mL) and H2SO4
(0.06 mL) were added sequentially. Stirring was then carried out for 1 min. A mixed
solution (3.5 mL) of glacial AcOH and aqueous H2O2 (30% wt) at a ratio of 2:3 (v/v)
was added and the mixture was vigorously stirred for 1 min. A solution of orga-
nostannyl compound 3 (9 mg) in CH2Cl2 (1 mL) was then added, and the mixture
was vigorously stirred at room temperature for 20 min. The reaction was quenched
by adding Na2S2O3 (2 M, 0.8 mL). The mixture was then partitioned and the organic
layer was collected, and the residual aqueous layer was back-extracted with CH2Cl2
(1 mL) twice. The organic layers collected were treated with seven large spatulas
worth of Na2SO4 and then gravity ﬁltered. The ﬁltrates were loaded onto a CH2Cl2-
preconditioned Alumina N cartridge followed by washing with a mixed solution of
Iodobiphenyl
IOFA 2
Scheme 1. Preparation of radioiodolabeled [123I]IOFA 2.
H.-L. Huang et al. / Biomaterials 34 (2013) 3355e33653358CH2Cl2 and MeOH (3 mL, 2:1 v/v). The ﬁltrates were concentrated under reduced
pressure, and the residue was further puriﬁed with HPLC using the eluent MeOH/
CHCl3 ¼ 1:99, tR ¼ 15.0 min (Radio). Fractions of [123I]iodooctafenbufen 2 that had
been isolated from several injections were combined followed by concentration
under reduced pressure to provide [123I]2 at 15% radiochemical yield (8.1 mCi, decay
corrected). The speciﬁc radioactivity and radiochemical purity were 36 GBq/mmole
and 99%, respectively. Regarding animal SPECT imaging, the cholangiocarcinoma
tumor-bearing rat and control rat were each injected with 0.76 mCi/1 mL and
1.39 mCi/1 mL, respectively.Fig. 2. HPLC chromatogram for [123I]IOFA 2 (15.05 min) prior to HPLC puriﬁcation. A normal
254 nm. (For interpretation of the references to color in this ﬁgure legend, the reader is re2.5. Bioassay of competitive inhibition of the substrate transfer (CIST) by COX
The procedure, as stated by the product supplier, was adopted throughout the
whole assay. In brief, inhibitors were diluted with ethanol to ﬁnal working concen-
trations that ranged either from 103e103 mM for positive controls SC560 and
SC58125 or from 101e105 mM for IOFA 2, fenbufen, and uridine, respectively. The
assay buffer (4 mL) was diluted with double distilled H2O (36 mL) to provide the
stock solution of assay buffer. The heme solution (88 mL) was diluted with the
above stock solution of assay buffer (1.91 mL). Each of the stock solutions (200 mL)phase column (Si-100) was employed. Red line: radioactivity and blue line: UV signal at
ferred to the web version of this article.)
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Fig. 3. Inhibition of substrate transfer by COX-1 (A) and COX-2 (B) in the presence of compounds that were tested at various concentrations. Uridine was used as a negative control,
whereas Sc-560 and Sc-58125 were used as COXs and COX-2 inhibitors, respectively. Triplicated measurements were performed for each concentration of compounds.
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including the stock solutions of enzyme, heme, arachidonic acid, and the colorimetric
substrate N,N,N’,N’-tetramethyl-1,4-benzenediamine dihydrochloride product
(TMPD) were cooled in a box that contained dry ice. In addition to uridine and IOFA 2
that were dissolved in H2O and DMSO, respectively, the other compounds were
dissolved inEtOH.Aftermixing the abovestock solutions of COX (10mL), heme (10mL),
compound tested (10 mL), assay buffer (150 mL), AA (20 mL) and TMPD (20 mL) tomake
a total volume of 220 mL. The serial dilution was performed in a 96-well microtiter
plate. The absorbance of each of the well was measured using UV detector at
lmax ¼ 595 nm. The software GraphPad 5 was used to plot the absorption vs. con-
centration. The percentage inhibitionwas calculated as {1 [(Absinitial AbsBKG(assay
bufferþEtOH))  (AbsinitialþC.T.  AbsBKG(assay bufferþC.T.))]/[(AbsAAþCOx  AbsBKG(assay
bufferþEtOH))]}  100%. BKG: background, C.T.: compounds tested.
2.6. Radioligand binding assay
An aliquot (10 mL) was drawn from the commercial stock solution of COXs
(200 mL). An additional 80 mL of Tris buffer (0.1 M, pH ¼ 8.0) was added to it. The
diluted solutions (90 uL) of COX-1 or COX-2 eachwere added by the radiotracer [123I]
IOFA 2 in EtOH, whereby the concentration ranged from 66 mCi/10 mL to 70 mCi/10 mL.
The whole mixture (100 mL) was incubated at 25 C for 15 min followed by puriﬁ-
cation using HPLC coupled with gel ﬁltration column. PBS buffer (0.1 M, pH ¼ 7.3)
was employed as the eluent, and the ﬂow rate was 1 mL/min.
2.7. Small animal CT/SPECT imaging study
All in vivo experiments were performed in compliance with the NHMRC Taiwan
Code of Practice for the care and use of animals for scientiﬁc purposes. Male
SpragueeDawley (SD) rats that were 49 weeks old were obtained from the Animal
Research Center (Chang-Gung Memorial Hospital, Taiwan). The rats were housed
under constant environmental conditions and were allowed free access to food andTable 1
Comparison of IC50 values that were obtained from the present assay and the
literature.
Substrate IC50 value
COX-1 (mM) COX-2 (mM)
This assay Lit. data This assay Lit. data
IOFA 2 >10 N.A. >10 N.A.
Resveratrol 3.9 1.56a 50 0.99b
SC-58125 >10 >10c 5 0.05c
SC-560 0.060 0.009d 2.5 6.3d
Uridine >10 N.A. >10 N.A.
Fenbufen >10 3.9e >10 8.1e
a Ref. [47].
b Ref. [48].
c Ref. [49].
d Ref. [50].
e Ref. [45].water throughout the experimental period. In vivo studies were performed in
a thioacetamide (TAA)-induced cholangiocarcinoma rat (37th week post admin-
istration) along with a normal rat as a control.
The rats were anaesthetized via inhalant isoﬂurane (Forthane, Abbott) in
200 mL/min oxygen during the imaging study. The imaging study was carried out at
the Nuclear Energy Research Institute. SPECT system (X-SPECT/CT, Gamma Media,
Northridge, CA, USA) was used for the small animal imaging study. The crude data
that was taken from the imaging study were further treated with Preclinical Multi-
Modality Data Analysis software (ver 3.2; PMOD Technologies Ltd, Zurich,
Switzerland).
2.8. MTT assay (cell viability assay)
The cell toxicity was assessed by a viability assay, MTT (3-(4,5-dimethyl-thiazol-
2-yl)-2,5-diphenyl tetrazolium bromide) reduction. In brief, T98 (human glioma cell
line) cells were plated in the 96-well plate (5000/well) and maintained at 37 C, 5%
CO2 incubator withMEM,10% fetal calf serum (Gibco, USA). After 24-hour pulse with
IOFA, 50 mL ofMTT (5mg/mL) was added to eachwell for four hours. After removal of
medium, 100 mL of DMSO was added to each well and the optical absorbance was
determined by a spectrophotometry using a plate reader at 570 nm.
3. Results and discussion
3.1. Radiochemical synthesis
Fenbufen analogs have seldom been reported except for their
use in an anti-inﬂammatory assay of a fenbufen amide library [45].
This might be probably due to its relatively limited structural var-
iability. The reactor-generated radioactive iodide ([123I]I) could be
introduced into OFA using a carbon on the aromatic ring. The
precursor organostannyl compound 3 was thus prepared via the
dehalostannylation of iodooctyl fenbufen amide (IOFA) 2 as out-
lined in Scheme 1.
Nonradioactive IOFA 2 was used to prepare organostannyl
compound 3 followed by radioiododestannylation to provide
radioactive [123I]IOFA 2 (Scheme 1). The very low polarity of IOFA 2
limited the choice of the eluent during column chromatography.
Thus, HPLC was virtually the only tool that was available for pur-
ifying IOFA 2 in spite of its limited capacity of 10 mg for each in-
jection. Radiochemical synthesis of [123I]IOFA 2 was relatively
straightforward. During the workup, a sufﬁcient amount of drying
agent of Na2SO4 was needed. Furthermore, incomplete removal of
the residual acetic acid after it was concentrated under reduced
pressure was a formidable problem. Thus, an additional procedure
for extracting, drying, and concentrating was repeated until the
ﬁnal white solid became odorless.
H.-L. Huang et al. / Biomaterials 34 (2013) 3355e33653360The poor solubility of IOFA 2 in the water-phase based saline
solution constituted another challenge because [123I]IOFA 2 was
obtained as a white solid after HPLC puriﬁcation. Prior to injecting
it into the tail vein for subsequent animal imaging, the saline
solution turned cloudy. Hence, the suspended white particlesFig. 4. HPLC chromatograms of a mixture of [123I]IOFA 2 with (A) COX-1 enzyme and (B) C
13.6 min). CPS: counts per second. (A) [123I]IOFA-COX-1 bound conjugate (tR ¼ 5.0 min) and
of the intact form [123I]IOFA 2 remained (13.6 min). (B) [123I]IOFA-COX-2 bound conjugate (t
was 79% and 21% of the intact form remained (13.6 min). (C) Chromatogram of solo injectiwere ﬁltered twice by using 0.45-mM ﬁlters. The relatively
low speciﬁc activity of [123I]IOFA 2 of less than 37 GBq/mmol
was due to the presence of a trace amount of an unknown
UV-inactive white solid, which may have decreased its speciﬁc
activity (Fig. 2).OX-2 enzyme. Binding yield ¼ peak area at 5 min/(peak area at 5min þ peak area at
residual unbound [123I]IOFA 2 (tR ¼ 13.6 min) where the binding yield was 56% and 44%
R ¼ 5.0 min) and residual unbound [123I]IOFA 2 (tR ¼ 13.6 min) where the binding yield
on of [123I]IOFA 2. Retention time ¼ 12.0 min.
Fig. 6. Molecular docking of IOFA 2 and COX-2. The side chain was extended into the channel behind the lobby occupied by the diaryl ring. (A) Illustration by electrostatic map. (B)
The 2-D illustration indicated the surrounded amino acid residues. Software: Discovery Studio 2.1 with Ligandﬁt. Active site was deﬁned by using ﬂurbiprofen complex of PDB entry
of 3RR3.
Fig. 5. Cell survival assay (MTT assay) of IOFA 2.
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Fig. 7. (A). SPECT/CT images of the normal rat with [123I]IOFA 2 were summated from 30 to 60 min post injection. The injection dose was 1.39 mCi/1 mL. Lv: Liver, (B) SPECT/CT
images of the CCA rat (feeding with TAA for 37 weeks) were summed from 30 min to 60 min post injection. The injection dose was 0.76 mCi/1 mL. Lv: liver, H: heart, T: tumor.
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(CIST) by COX enzymes
Both the COX-2 selective (SC-58125) and highly COX active but
not selective (SC-560) inhibitors were used as controls throughout
the assay (Fig. 3). The assay results showed that IOFA 2 displayed
marginal competitive inhibition against the reduction of the col-
orimetric substrate by COX-1 and COX-2.
The present assaywas based on assessing the reductionpotential
that was catalyzed by POX, which was responsible for the second
catalysis of COX. Furthermore, two intermediates were generated
from the AA-heme-COX complex that could oxidize N,N,N’,N’-tet-
ramethyl-1,4-benzenediamine dihydrochloride (TMPD) to provide
the colorimetric product [11,46]. It has been speculated that POX
inactivation involves the oxyferryl heme group, whereas COX
inactivation involves a tyrosyl radical [46]. Both of the two positive
controls could potentially inhibit POX and thereby block COX
function (Table 1). Speciﬁcally, COX-2 inhibition is caused bybinding
to Ecat. These inhibitors are thus classiﬁed as being competitive in-
hibitors. Clearly, IOFA 2 was not one such competitive inhibitor.
As a result, the binding afﬁnity of the substrate toward the ﬁrst
catalytic binding site could not be evaluated very well. Another
method that entailed using radioligand binding assay was therefore
adopted as is described below.
3.3. Radioligand binding assay
The basis of the assay was based on the differential retention
times for HPLC of the radioligand-enzyme complexes and the un-
bound radioligand. Prior to submitting the binding product mix-
tures for HPLC analysis, a small aliquot of enzyme (10 mL) from the
commercial stock solution (200 mL) was introduced to ensure the
formation of enough radioligandeenzyme complex prior to anal-
ysis. The pronounced nonpolarity of the radioligand [123I]IOFA 2Fig. 8. Immunostaining study: (A) Negative cytoplasmic immunostaining of COX-1 of a norm
of a CCA rat (400). (C) Negative cytoplasmic immunostaining of COX-2 of a normal bile du
rat (400).might prevent using polar eluents for chromatography. For us,
a water-based PBS buffer as an eluting solvent did not alter the
retention time of [123I]IOFA 2. The chromatogram showed an
expected pattern in that unbound [123I]IOFA 2 with a smaller mo-
lecular size was retarded due to its elution through the mini-
aturized fractured path (Fig. 4). In contrast, the bound complex
with its larger molecular size should have been eluted along the
main fractured path thereby traveling at a more rapid speed.
Whereas the substrate transfer (CIST) assay showed that IOFA 2
was neither a potent nor selective COX inhibitor, the radioligand
binding assay as shown above (Fig. 4), indicated its preferential
binding afﬁnity toward COX-2 rather than COX-1. Its afﬁnity ratio
was 1.4:1 when calculated from radioactivity fraction of 76% vs.
56%. Because IOFA 2 did not exhibit a competent inhibition proﬁle
similar to that of traditional COX-2 inhibitors, the binding site
should be conﬁned to Eallo. Its role in regulation might be similar to
common non-substrate FAs. Interestingly, IOFA 2 exhibited a cell-
growth inhibition proﬁle when acting against T98 cells (30%
inhibition at 10 mM, Fig. 5) that differentiates it from common non-
substrate FAs. Modeling was used to correlate its structure and
reactivity (Fig. 6A). Of note, we observed close contact between
Tyr385 and the amido hydrogen, which might compete with AA to
carry out hydrogen abstraction during the ﬁrst rate-determining
step of COX activity (Fig. 6B). In addition, the biphenyl ring of
IOFA 2mimics the cyclopentane ring of oxidized AA that is formed
from the addition of oxygen to AA, which constitutes the second
rate-determining step. Thus, IOFA 2 seems to displace AA in terms
of COX binding but does not appear to inhibit the formation of the
radical cation of Tyr385-heme complex as in the case of POX in-
hibitors. As shown in Fig. 6B, the 8-carbon side chain of IOFA 2was
capable of extending into a narrow bag in the active site that could
induce a foot-like ﬁt with the structure of IOFA 2. The foot-like
conformation of the IOFA-COX complex may mimic the L-shape
conformation of the AA-COX complex. The stabilization that wasal bile duct of a normal rat (400). (B) Positive cytoplasmic immunostaining of COX-1
ct of a normal rat (400). (D) Positive cytoplasmic immunostaining of COX-2 of a CCA
H.-L. Huang et al. / Biomaterials 34 (2013) 3355e33653364gained by ﬁtting the octyl side chainmight have triggered apoptotic
signaling as described for AEA. To serve as a noninvasive imaging
tracer in vivo, the binding complex should be durable during
imaging processing. In an in vitro monitoring by HPLC with gel
ﬁltration column, about half of the radioactivity of the binding
complexes was still intact after incubation for 40 min (data not
shown). With this information in mind, the subsequent in vivo
imaging frame was therefore set from 30 min to 60 min post iv
injection.
3.4. Tumor imaging
Cholangiocarcinoma (CCA) tumor rat [51e57] was injected with
an aliquot of [123I]IOFA 2 (0.76 mCi/1 mL) via tail vein to obtain 1 h
worth of SPECT imaging data (Fig. 7 (A)). The normal rat was
injected with the residual aliquot of [123I]IOFA 2 in a dose of
1.39 mCi/1 mL (Fig. 7 (B)). Although the two injections were con-
ditioned by adjusting the solvent volume to attain equivalent
speciﬁc activities, the normal rat received more speciﬁc activity.
The in vivo distribution of radioactivity in the normal rat showed
a homogeneous pattern, that was localized mainly in the liver and
partly in the heart 30 min post administration (Fig. 7A). In contrast,
a heterogeneous distribution was observed in the liver of the CCA
tumor rat. Moreover, those regions that showed hot spots as indi-
cated were equivalent to the white matter in the photograph that
was taken of the same rat after it was sacriﬁced ((Fig. 7B), right
lower corner). The white matter is an indication of the tumor lesion
as judged on the basis of the clinical experience.
Specimens of the liver from each of the two rats were further
analyzed by histological stainings against both COX-1 and COX-2
(Fig. 8). Clearly, the positive stainings of both the COX-1 and COX-
2 were solely found in the bile duct of CCA tumor rat but not of
the normal rat. The higher radioactivity accumulation in CCA rat
may be because of a higher expression level of COX (s) or because of
mutant COX (s) with higher binding activity. The latter assumption
needs to be conﬁrmed in a future study and could not be over-
ridden by the current study. Although [123I]IOFA 2 exerted a mixed
COX binding afﬁnity pattern (Fig. 4), the accumulation of a consid-
erable amount of radioactivity in the heart was remarkable
(Fig. 7B).
4. Conclusion
A 4-step facial synthesis was employed to provide [123I]IOFA 2. A
radiochemical yield of 15% and a speciﬁc activity of less than
37 GBq/mmol were acceptable for SPECT imaging. The binding
analysis of [123I]IOFA 2 and COX using HPLC in conjugation with
a gel ﬁltration column showed preferable afﬁnity toward COX-2
compared to COX-1. The results from both the noninvasive SPECT
images of [123I]IOFA 2 in the CCA tumor rat and the photographs
after it was sacriﬁced were correlated with each other with respect
to the hot spots and white matters in the tumor lesion. The
expression levels of both COXs in the livers of the CCA tumor rat
were signiﬁcantly higher than that of the normal rat in terms of
immunohistological staining. The marked accumulation of radio-
active [123I]IOFA 2 clearly demonstrated its potential as an imaging
agent for diagnosing tumors. Tumor-associated inﬂammation could
be imaged using [123I]IOFA 2 by SPECT as well.
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